A novel methionyl-tRNA synthetase inhibitor targeting gram-positive bacterial pathogens
Antimicrobial Agents and Chemotherapy · 2024
DOI: 10.1128/aac.00745-24 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2024. Verfasst von Nora M R Molasky und 7 weiteren Autor:innen. Beteiligte Einrichtung: Center for Emerging and Re-emerging Infectious Diseases, Department of Medicine, Division of Allergy and Infectious Disease, University of Washington…. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Methionine-tRNA Ligase, Microbial Sensitivity Tests, Methicillin-Resistant Staphylococcus aureus. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, HHS | National Institutes of Health.
Abstract (Originalsprache)
New antibiotics are needed to treat gram-positive bacterial pathogens. MRS-2541 is a novel inhibitor of methionyl-tRNA synthetase with selective activity against gram-positive bacteria. The minimum inhibitory concentrations (MICs) against Staphylococcus aureus, Streptococcus pyogenes, and Enterococcus species range from 0.063 to 0.5 µg/mL. Given orally to mice at 50 mg/kg every 8 hours, MRS-2541 shows sustained plasma levels well above these MICs. In the mouse thigh infection model, MRS-2541 decreased methicillin-resistant Staphylococcus aureus and Streptococcus pyogenes bacterial loads to the same degree as linezolid. MRS-2541 is a promising new antibiotic for development against skin and soft tissue infections.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Emerging and Re-emerging Infectious Diseases, Department of Medicine, Division of Allergy and Infectious Disease, University of Washington, Seattle, Washington, USA.
- Department of Biochemistry, University of Washington, Seattle, Washington, USA.
- Therapeutic Systems Research Laboratories, Inc., Ann Arbor, Michigan, USA.
ORCID-Profile: Erkang Fan, Frederick S Buckner
Förderung
- NIAID NIH HHS
- HHS | National Institutes of Health
Zitieren
APA
Molasky, N. M. R., Zhang, Z., Gillespie, J. R., Domagala, J., Reyna, D., Lipka, E., Fan, E., & Buckner, F. S. (2024). A novel methionyl-tRNA synthetase inhibitor targeting gram-positive bacterial pathogens. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.00745-24
Vancouver
Molasky NMR, Zhang Z, Gillespie JR, Domagala J, Reyna D, Lipka E, et al. A novel methionyl-tRNA synthetase inhibitor targeting gram-positive bacterial pathogens. Antimicrobial Agents and Chemotherapy. 2024. doi:10.1128/aac.00745-24
BibTeX
@article{Molasky2024,
author = {Molasky, Nora M R and Zhang, Zhongsheng and Gillespie, J Robert and Domagala, John and Reyna, Dawn and Lipka, Elke and Fan, Erkang and Buckner, Frederick S},
title = {A novel methionyl-tRNA synthetase inhibitor targeting gram-positive bacterial pathogens},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2024},
doi = {10.1128/aac.00745-24}
}
EUVIMED